Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

Human and Experimental Toxicology - Tập 18 Số 1 - Trang 17-26 - 1999
Michael Amantea1, Mary S. Newman1, Timothy M. Sullivan2, Alan Forrest3, Peter K. Working1
1SEQUUS Pharmaceuticals, Inc., Menlo Park, California, USA
2Battelle, Columbus, Ohio, USA
3Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, New York, USA

Tóm tắt

1 The multiple dose pharmacokinetics of pegylated liposomal doxorubicin (PL-DOX), known as DOXIL® (US) and CAELYX® (EU), was characterized in dogs and a pharmacokinetic/pharmacodynamic model to identify a relationship between drug exposure and the probability of observing treatment-related palmarplantar erythrodysesthesia (PPE) was developed. 2 Twenty dogs were assigned to PL-DOX groups (2/sex/ group) that received intravenous PL-DOX doses of 0.5 mg/kg q1, 2, or 4 weeks; 1.0 mg/kg q2weeks; or 1.5 mg/kg q4weeks for 12 weeks. Blood was collected for HPLC analysis of doxorubicin concentration pre-dose and periodically up to 120 h after dosing three times during treatment. 3 Plasma drug concentration was modeled using iterative 2-stage analysis. Dermal lesions (PPE) were scored twice weekly for six regions of each dog using a 0-6 severity scale; maximum severity was 36. PPE score data were modeled using an approach in which the% probability of PPE was related to a hypothetical effect site by a series of Hill-type functions. 4 Pharmacokinetics were best modeled as a one-compartment open model. Vss (ml/kg), CLt (ml/hr/kg) and half-life (h) were 44.1, 1.39 and 23.1, respectively. Cmax increased linearly with dose. CLt decreased with repeated doses. 5 A two-compartment pharmacodynamic model, which correctly predicted 97% of the observed lesion severity, was developed to establish the relationship of lesion severity to dose intensity (a measure of drug exposure incorporating the effect of both dose level and dosing frequency, which can be expressed in units of mg/kg/week). The model demonstrated that maximal PPE was positively correlated with dose intensity, the major factor that affects the incidence and severity of dermal lesions. 6 The model can be used to predict acceptable dose intensities in humans utilizing body surface area conversion factors and comparative AUCs for dogs and humans. It predicts that a dose intensity of 10-12.5 mg/m2 of PL-DOX will be well tolerated in patients. The results of recent clinical studies are consistent with this prediction.

Từ khóa


Tài liệu tham khảo

10.3109/08982109409037065

10.1002/j.1552-4604.1996.tb04152.x

Huang SK, 1992, Cancer Research, 52, 6774

10.1038/bjc.1997.84

10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1

Huang SK, 1994, American Journal of Pathology, 143, 10

Working PK, 1996, Human and Experimental Toxicology, 15, 752, 10.1177/096032719601500906

10.7326/0003-4819-101-6-798

Comandone A, 1993, Anticancer Research, 13, 1781

Samuels BL, 1987, Cancer Treatment Reports, 71, 971

10.1200/JCO.1995.13.2.424

Matsuyama JR, 1989, Drug Intelligence and Clinical Pharmacology, 23, 778

10.1093/jnci/85.17.1432

10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H

10.1200/JCO.1997.15.3.987

10.1200/JCO.1997.15.10.3185

10.1200/JCO.1997.15.9.3164

Newman MS, 1996, The Toxicologist, 30, 103

Prevost G., 1977, Estimation of normal probability density function from samples measured with nonnegligible and non-constant dispersion (internal report)

10.3109/03602538409015063

10.3109/03602538409015066

10.1016/0010-468X(79)90025-4

D'Argenio DZ, 1992, ADAPT Users Guide (Biomedical Simulations Resource)

Jusko WJ., 1992, Principles of Therapeutic Drug Monitoring

10.1093/biomet/66.2.237

Hill AV., 1910, Journal of Physiology (London), 40, IV

10.1023/A:1018907715905

Vukelja SJ, 1989, Annals of Internal Medicine, 111, 688, 10.7326/0003-4819-111-8-688

10.1093/jnci/86.7.557

Vail DM, 1998, Clinical Cancer Research, 4, 1567

10.1016/S0009-9236(97)90162-4

Freireich EJ, 1966, Cancer Chemotherapy Reports, 50, 219

Thông tin
Thông tin xuất bản

Human and Experimental Toxicology

Tập 18 Số 1

17-26

Thông tin tác giả